Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Terrence Bruner

Plastic Surgery Anderson, SC Medical Doctor

NPI 1588803530 CMS profile 298307

7 Linwa Blvd, Anderson, SC 29621

Open in the dashboard

General payments

$2,148

104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Terrence Bruner of Anderson, SC is reported in the CMS Open Payments database as having received $2,148 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $510 19
2024 General $417 18
2023 General $320 16
2022 General $306 16
2021 General $276 15
2020 General $76 5
2019 General $242 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Terrence Bruner
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Terrence Bruner were reported at $510. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Terrence Bruner Plastic Surgery median Middle half National median
2019 $242 $371 $122–$1,483 $163
2020 $76 $158 $52–$438 $114
2021 $276 $249 $87–$752 $132
2022 $306 $274 $102–$793 $149
2023 $320 $299 $113–$891 $160
2024 $417 $361 $124–$1,062 $164
2025 $510 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eisai Inc. $201 9 payments
  2. AstraZeneca Pharmaceuticals LP $115 6 payments
  3. TELA Bio, Inc. $111 3 payments
  4. Mentor Worldwide LLC $105 3 payments
  5. AbbVie, Inc. $92 4 payments
  6. Merck Sharp & Dohme Corporation $89 4 payments
  7. Seattle Genetics, Inc. $85 5 payments
  8. Sientra, Inc. $75 3 payments
  9. Celgene Corporation $72 3 payments
  10. Jazz Pharmaceuticals Inc. $71 4 payments
  11. Other $1,132 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,137 103 payments
  2. Education $11 1 payment
Products named General payments · program years 2019–2025
  1. Lenvima $201 9 payments
  2. MENTOR MemoryGel Resterilizable Gel Sizer $105 3 payments
  3. KEYTRUDA $89 4 payments
  4. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $75 3 payments
  5. ZEPZELCA $71 4 payments
  6. OviTex 2S $68 2 payments
  7. BOTOX $62 4 payments
  8. REBLOZYL $59 2 payments
  9. TAGRISSO $59 3 payments
  10. PROMACTA $52 3 payments
  11. Other $1,422 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

76

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$354

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

75%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 28 $133
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 29 $113
Pregabalin Generic 19 $108

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$81,217

Medicare's payments for the services billed

Medicare patients

95

Average age 74

Services billed

223

58 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 35%
Cancer 33%
Ischemic heart disease 24%
Diabetes 22%
Depression 22%
Heart failure 16%
Osteoporosis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Lenvima
  • Eisai Inc. $46
$46 — —
ENHERTU
  • Daiichi Sankyo Inc. $26
$26 — —
REBLOZYL
  • Celgene Corporation $25
$25 — —
CALQUENCE
  • AstraZeneca Pharmaceuticals LP $23
$23 — —
TIVDAK
  • Genmab U.S., Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record